X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Forma Therapeutics To Be Acquired By Novo Nordisk For $1.1bn

Content Team by Content Team
9th September 2022
in Facilities & Operation, News
Forma Therapeutics To Be Acquired By Novo Nordisk For $1.1bn

On September 1, 2022, Novo Nordisk and Forma Therapeutics revealed that Novo Nordisk would buy Forma Therapeutics for for $1.1 billion. With the purchase of Forma, Novo Nordisk now has access to the company’s inventory of sickle cell disease (SCD) and rare blood drugs, including etavopivat, its top development candidate. The deal is anticipated to be finalised in the final quarter of 2022.

Etavopivat is a once-daily, investigational oral, specific pyruvate kinase-R (PKR) stimulator that is being created to help SCD patients with anaemia and red blood cell health. In accordance with a company press release, it stimulates the natural PKR activity of red blood cells to lower tiers of the metabolite 2,3-diphosphoglyceric acid. This is intended to help sickle haemoglobin hold onto oxygen for a longer period of time, which will reduce polymerization, hemolysis, and sickling. It is currently being studied in a global Phase II/III trial in SCD patients and a Phase II trial in SCD patients who require transfusions as well as those with thalassemia, another genetic hemoglobinopathy.

For more than 40 years, Novo Nordisk has fought to create and provide patients with rare and fatal diseases with transformational therapies. In a news release from Novo Nordisk, executive vice-president and head of rare illness Ludovic Helfgott stated, they are taking a step ahead in expanding their sickle cell disease pipeline by integrating Forma’s differentiated strategy to meet unmet requirements for patients. They hope to create a market-leading portfolio of medications that will address both the symptoms and fundamental causes of sickle cell disease.

According to the press release, Frank D. Lee, president and CEO of Forma Therapeutics, the announcement is indeed an important milestone that accelerates Forma’s aim to enhance the lives of people with sickle cell disease and other critical haematological disorders.” “To maximise their impact for sickle cell patients all over the world who urgently require new treatment choices, Novo Nordisk will work very closely with the sickle cell community. They are excited to collaborate with Novo Nordisk to improve innovation, accessibility, and care quality for patients while acting as a dependable partner for their communities.

Previous Post

Merck Reviews Five-Year Lung Cancer Studies of Keytruda

Next Post

Anti-Evolocumab Antibodies Are Now Available From Bio-Rad

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Anti-Evolocumab Antibodies Are Now Available From Bio-Rad

Anti-Evolocumab Antibodies Are Now Available From Bio-Rad

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In